Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden

The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 123; pp. 83 - 91
Main Authors Satzger, Imke, Leiter, Ulrike, Gräger, Nikolai, Keim, Ulrike, Garbe, Claus, Gutzmer, Ralf
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2019
Elsevier Science Ltd
Subjects
Online AccessGet full text
ISSN0959-8049
1879-0852
1879-0852
DOI10.1016/j.ejca.2019.07.004

Cover

Abstract The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. •The new American Joint Committee of Cancer (AJCC) classification for melanoma is controversially discussed, particular with regard to stage III.•This is crucial because the correct prognostication in stage III patients in extremely important for adjuvant treatment decision.•Sentinel node tumor load is a relevant prognostic parameter.•The diameter of the largest melanoma deposit enhances the prognostic value in stage III patients.
AbstractList The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.
The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. •The new American Joint Committee of Cancer (AJCC) classification for melanoma is controversially discussed, particular with regard to stage III.•This is crucial because the correct prognostication in stage III patients in extremely important for adjuvant treatment decision.•Sentinel node tumor load is a relevant prognostic parameter.•The diameter of the largest melanoma deposit enhances the prognostic value in stage III patients.
1Background The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. Patients and methods A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. Results By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). Conclusion The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.
The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.BACKGROUNDThe tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.PATIENTS AND METHODSA total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).RESULTSBy univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.CONCLUSIONThe prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.
Author Gutzmer, Ralf
Leiter, Ulrike
Gräger, Nikolai
Keim, Ulrike
Garbe, Claus
Satzger, Imke
Author_xml – sequence: 1
  givenname: Imke
  orcidid: 0000-0001-5983-2125
  surname: Satzger
  fullname: Satzger, Imke
  email: satzger.imke@mh-hannover.de
  organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany
– sequence: 2
  givenname: Ulrike
  surname: Leiter
  fullname: Leiter, Ulrike
  organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
– sequence: 3
  givenname: Nikolai
  surname: Gräger
  fullname: Gräger, Nikolai
  organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany
– sequence: 4
  givenname: Ulrike
  surname: Keim
  fullname: Keim, Ulrike
  organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
– sequence: 5
  givenname: Claus
  surname: Garbe
  fullname: Garbe, Claus
  organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
– sequence: 6
  givenname: Ralf
  surname: Gutzmer
  fullname: Gutzmer, Ralf
  organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31677550$$D View this record in MEDLINE/PubMed
BookMark eNqFkcGK1TAUhoOMOHdGX8CFBNy4aU3apkkHNzLoKIwIouuQpidMaprUpK3ctzeXO8PAXYyrwOH7Dif_f4HOfPCA0GtKSkpo-34sYdSqrAjtSsJLQppnaEcF7woiWHWGdqRjXSFI052ji5RGQggXDXmBzmvacs4Y2aHpGzjlw6SKNIO2xmqc1rjZTTlsPZ7VYsEvCf-1yx2eQ7KL3QCnPLMeHHb7ab7DPgyQrvAPcLAprwEH84gs6xQi7tc4gH-JnhvlEry6fy_Rr8-ffl5_KW6_33y9_nhb6KZmSzGYitKa910rCKXQk6bXqmVUg2GDGtoBdK97zmhlNG9rIwwVmjFhul63XVXXl-jdce8cw58V0iInmzS4_FUIa5JVTWnLhKh4Rt-eoGNYo8_XZaom-YSGs0y9uafWfoJBztFOKu7lQ5AZEEdAx5BSBCO1XXJ4wS9RWScpkYfO5CgPnclDZ5JwmTvLanWiPmx_UvpwlCDHuFmIMunclIbBRtCLHIJ9Wr860bWz3mrlfsP-f_I_-5_EsQ
CitedBy_id crossref_primary_10_1038_s41379_021_00835_5
crossref_primary_10_1186_s12885_022_09705_y
crossref_primary_10_23736_S2784_8671_21_06958_3
crossref_primary_10_1007_s15004_020_8241_y
crossref_primary_10_3390_cancers13102319
crossref_primary_10_1016_j_ejca_2020_04_022
crossref_primary_10_3390_cancers13122902
crossref_primary_10_1002_jso_27438
crossref_primary_10_1007_s00761_022_01108_9
crossref_primary_10_1186_s42047_020_00083_y
crossref_primary_10_1080_0284186X_2021_1892820
crossref_primary_10_1080_0284186X_2023_2238558
crossref_primary_10_1016_j_ejca_2024_113912
crossref_primary_10_3389_fonc_2024_1416685
crossref_primary_10_1097_XCS_0000000000000088
Cites_doi 10.1056/NEJMoa1708539
10.1002/1097-0142(20010601)91:11<2110::AID-CNCR1239>3.0.CO;2-Q
10.1016/j.ejca.2013.08.023
10.1002/cncr.25074
10.1016/j.ejca.2019.05.020
10.1200/JCO.2010.31.6760
10.1016/S1470-2045(16)00141-8
10.1200/JCO.2018.36.15_suppl.9500
10.1200/JCO.2011.37.1112
10.1097/CMR.0000000000000081
10.1016/j.ejca.2018.02.022
10.1002/cncr.24298
10.1200/JCO.2009.23.4799
10.3322/caac.21409
10.1200/JCO.2018.36.15_suppl.9591
10.1056/NEJMoa1709030
10.1016/j.ejca.2017.11.023
10.1056/NEJMoa1802357
ContentType Journal Article
Copyright 2019 Elsevier Ltd
Copyright © 2019 Elsevier Ltd. All rights reserved.
Copyright Elsevier Science Ltd. Dec 2019
Copyright_xml – notice: 2019 Elsevier Ltd
– notice: Copyright © 2019 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Science Ltd. Dec 2019
DBID AAYXX
CITATION
NPM
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1016/j.ejca.2019.07.004
DatabaseName CrossRef
PubMed
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed

AIDS and Cancer Research Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-0852
EndPage 91
ExternalDocumentID 31677550
10_1016_j_ejca_2019_07_004
S0959804919304046
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABGSF
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABUDA
ABWVN
ABXDB
ACDAQ
ACIEU
ACIUM
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IHE
J1W
K-O
KOM
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZXP
~G-
AACTN
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AHPSJ
AJBFU
AJOXV
AMFUW
DOVZS
EFLBG
LCYCR
RIG
ZA5
AAYXX
AGRNS
CITATION
NPM
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c435t-df21137b968011eb04bca651cef5dad6decbcb7512fc763f8f18c558f9bc69233
IEDL.DBID AIKHN
ISSN 0959-8049
1879-0852
IngestDate Fri Sep 05 09:18:48 EDT 2025
Sat Jul 26 02:28:11 EDT 2025
Wed Feb 19 02:31:07 EST 2025
Thu Apr 24 23:10:11 EDT 2025
Tue Jul 01 02:56:55 EDT 2025
Fri Feb 23 02:48:47 EST 2024
Tue Aug 26 19:28:13 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Tumor burden
Prognosis
Sentinel lymph node
Melanoma
Language English
License Copyright © 2019 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c435t-df21137b968011eb04bca651cef5dad6decbcb7512fc763f8f18c558f9bc69233
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5983-2125
PMID 31677550
PQID 2330968475
PQPubID 2047469
PageCount 9
ParticipantIDs proquest_miscellaneous_2311658827
proquest_journals_2330968475
pubmed_primary_31677550
crossref_citationtrail_10_1016_j_ejca_2019_07_004
crossref_primary_10_1016_j_ejca_2019_07_004
elsevier_sciencedirect_doi_10_1016_j_ejca_2019_07_004
elsevier_clinicalkey_doi_10_1016_j_ejca_2019_07_004
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2019
2019-12-00
20191201
PublicationDateYYYYMMDD 2019-12-01
PublicationDate_xml – month: 12
  year: 2019
  text: December 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle European journal of cancer (1990)
PublicationTitleAlternate Eur J Cancer
PublicationYear 2019
Publisher Elsevier Ltd
Elsevier Science Ltd
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Science Ltd
References Balch, Gershenwald, Soong (bib4) 2009 Dec 20; 27
Satzger, Meier, Zapf (bib13) 2014 Oct; 24
Gershenwald, Scolyer, Hess (bib5) 2017 Nov; 67
Van der Ploeg, van Akkooi, LU (bib9) 2014 Jan; 50
Verver, van Klaveren, van Akkooi (bib17) 2018 Jun; 96
Grob, Schadendorf, Lorigan (bib6) 2018 Mar; 91
van der Ploeg, van Akkooi, Rutkowski (bib8) 2011 Jun 1; 29
Satzger, Meier, Voelker (bib10) 2011; 29
Weber, Mandala, Del Vecchio (bib1) 2017 Nov 9; 377
Larkin, Hauschild, Santinami (bib18) 2018; 36
Eggermont, Blank, Mandala (bib19) 2019 Jul; 116
Madu, Franke, Van de Wiel (bib16) 2018; 36
Long, Hauschild, Santami (bib2) 2017 Nov 9; 377
Pflugfelder, Kochs, Blum (bib15) 2013 Jun; 11
Eggermont, Blank, Mandala (bib3) 2018; 378
Meier, Satzger, Völker (bib14) 2010 Jul 1; 116
Murali, Cochran, Cook (bib11) 2009. Nov 1; 115
Starz, Balda, Kramer (bib7) 2001; 91
Leiter, Stadler, Mauch (bib12) 2016 Jun; 17
Weber (10.1016/j.ejca.2019.07.004_bib1) 2017; 377
Eggermont (10.1016/j.ejca.2019.07.004_bib3) 2018; 378
Satzger (10.1016/j.ejca.2019.07.004_bib10) 2011; 29
Eggermont (10.1016/j.ejca.2019.07.004_bib19) 2019; 116
Verver (10.1016/j.ejca.2019.07.004_bib17) 2018; 96
Larkin (10.1016/j.ejca.2019.07.004_bib18) 2018; 36
Balch (10.1016/j.ejca.2019.07.004_bib4) 2009; 27
Grob (10.1016/j.ejca.2019.07.004_bib6) 2018; 91
Satzger (10.1016/j.ejca.2019.07.004_bib13) 2014; 24
Starz (10.1016/j.ejca.2019.07.004_bib7) 2001; 91
Murali (10.1016/j.ejca.2019.07.004_bib11) 2009; 115
Leiter (10.1016/j.ejca.2019.07.004_bib12) 2016; 17
Gershenwald (10.1016/j.ejca.2019.07.004_bib5) 2017; 67
Pflugfelder (10.1016/j.ejca.2019.07.004_bib15) 2013; 11
Van der Ploeg (10.1016/j.ejca.2019.07.004_bib9) 2014; 50
Meier (10.1016/j.ejca.2019.07.004_bib14) 2010; 116
van der Ploeg (10.1016/j.ejca.2019.07.004_bib8) 2011; 29
Madu (10.1016/j.ejca.2019.07.004_bib16) 2018; 36
Long (10.1016/j.ejca.2019.07.004_bib2) 2017; 377
References_xml – volume: 36
  year: 2018
  ident: bib18
  article-title: Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification
  publication-title: J Clin Oncol
– volume: 50
  start-page: 111
  year: 2014 Jan
  end-page: 120
  ident: bib9
  article-title: The prognostic significance of sentinel node tumor burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients
  publication-title: Eur J Cancer
– volume: 36
  year: 2018
  ident: bib16
  article-title: External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III
  publication-title: J Clin Oncol
– volume: 377
  start-page: 1813
  year: 2017 Nov 9
  end-page: 1823
  ident: bib2
  article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
  publication-title: N Engl J Med
– volume: 27
  start-page: 6199
  year: 2009 Dec 20
  end-page: 6206
  ident: bib4
  article-title: Final version of 2009 AJCC melanoma staging and classification
  publication-title: J Clin Oncol
– volume: 29
  start-page: 2206
  year: 2011 Jun 1
  end-page: 2214
  ident: bib8
  article-title: Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria
  publication-title: J Clin Oncol
– volume: 116
  start-page: 148
  year: 2019 Jul
  end-page: 157
  ident: bib19
  article-title: Prognostic and predictive value of AJCC-8 staging in the phase 3 EORTC 1325/Keynote-054 trial of pembrolizumab vs. placebeo in resected high-risk stage III melanoma
  publication-title: Eur J Cancer
– volume: 17
  start-page: 757
  year: 2016 Jun
  end-page: 767
  ident: bib12
  article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
  publication-title: Lancet Oncol
– volume: 116
  start-page: 3178
  year: 2010 Jul 1
  end-page: 3188
  ident: bib14
  article-title: Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center
  publication-title: Cancer
– volume: 67
  start-page: 472
  year: 2017 Nov
  end-page: 492
  ident: bib5
  article-title: Evidence based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
  publication-title: CA Cancer J Clin
– volume: 96
  start-page: 25
  year: 2018 Jun
  end-page: 33
  ident: bib17
  article-title: Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations
  publication-title: Eur J Cancer
– volume: 115
  start-page: 5026
  year: 2009. Nov 1
  end-page: 5037
  ident: bib11
  article-title: Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma
  publication-title: Cancer
– volume: 29
  start-page: 3588
  year: 2011
  end-page: 3590
  ident: bib10
  article-title: Parameters predicting prognosis in melanoma sentinel nodes
  publication-title: J Clin Oncol
– volume: 91
  start-page: 2110
  year: 2001
  end-page: 2121
  ident: bib7
  article-title: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma
  publication-title: Cancer
– volume: 91
  start-page: 168
  year: 2018 Mar
  end-page: 170
  ident: bib6
  article-title: Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
  publication-title: Eur J Cancer
– volume: 377
  start-page: 1824
  year: 2017 Nov 9
  end-page: 1835
  ident: bib1
  article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
  publication-title: N Engl J Med
– volume: 378
  start-page: 1789
  year: 2018
  end-page: 1801
  ident: bib3
  article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma
  publication-title: N Engl J Med
– volume: 24
  start-page: 454
  year: 2014 Oct
  end-page: 461
  ident: bib13
  article-title: Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?
  publication-title: Melanoma Res
– volume: 11
  start-page: 563
  year: 2013 Jun
  end-page: 602
  ident: bib15
  article-title: S3-guideline “diagnosis, therapy and follow-up of melanoma” -- short version
  publication-title: J Dtsch Dermatol Ges
– volume: 377
  start-page: 1813
  issue: 19
  year: 2017
  ident: 10.1016/j.ejca.2019.07.004_bib2
  article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1708539
– volume: 91
  start-page: 2110
  year: 2001
  ident: 10.1016/j.ejca.2019.07.004_bib7
  article-title: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma
  publication-title: Cancer
  doi: 10.1002/1097-0142(20010601)91:11<2110::AID-CNCR1239>3.0.CO;2-Q
– volume: 50
  start-page: 111
  issue: 1
  year: 2014
  ident: 10.1016/j.ejca.2019.07.004_bib9
  article-title: The prognostic significance of sentinel node tumor burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.08.023
– volume: 116
  start-page: 3178
  issue: 13
  year: 2010
  ident: 10.1016/j.ejca.2019.07.004_bib14
  article-title: Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center
  publication-title: Cancer
  doi: 10.1002/cncr.25074
– volume: 116
  start-page: 148
  year: 2019
  ident: 10.1016/j.ejca.2019.07.004_bib19
  article-title: Prognostic and predictive value of AJCC-8 staging in the phase 3 EORTC 1325/Keynote-054 trial of pembrolizumab vs. placebeo in resected high-risk stage III melanoma
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2019.05.020
– volume: 29
  start-page: 2206
  issue: 16
  year: 2011
  ident: 10.1016/j.ejca.2019.07.004_bib8
  article-title: Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.31.6760
– volume: 17
  start-page: 757
  issue: 6
  year: 2016
  ident: 10.1016/j.ejca.2019.07.004_bib12
  article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00141-8
– volume: 36
  year: 2018
  ident: 10.1016/j.ejca.2019.07.004_bib16
  article-title: External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.15_suppl.9500
– volume: 29
  start-page: 3588
  issue: 26
  year: 2011
  ident: 10.1016/j.ejca.2019.07.004_bib10
  article-title: Parameters predicting prognosis in melanoma sentinel nodes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.1112
– volume: 11
  start-page: 563
  issue: 6
  year: 2013
  ident: 10.1016/j.ejca.2019.07.004_bib15
  article-title: S3-guideline “diagnosis, therapy and follow-up of melanoma” -- short version
  publication-title: J Dtsch Dermatol Ges
– volume: 24
  start-page: 454
  issue: 5
  year: 2014
  ident: 10.1016/j.ejca.2019.07.004_bib13
  article-title: Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?
  publication-title: Melanoma Res
  doi: 10.1097/CMR.0000000000000081
– volume: 96
  start-page: 25
  year: 2018
  ident: 10.1016/j.ejca.2019.07.004_bib17
  article-title: Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2018.02.022
– volume: 115
  start-page: 5026
  issue: 21
  year: 2009
  ident: 10.1016/j.ejca.2019.07.004_bib11
  article-title: Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma
  publication-title: Cancer
  doi: 10.1002/cncr.24298
– volume: 27
  start-page: 6199
  issue: 36
  year: 2009
  ident: 10.1016/j.ejca.2019.07.004_bib4
  article-title: Final version of 2009 AJCC melanoma staging and classification
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.4799
– volume: 67
  start-page: 472
  issue: 6
  year: 2017
  ident: 10.1016/j.ejca.2019.07.004_bib5
  article-title: Evidence based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21409
– volume: 36
  year: 2018
  ident: 10.1016/j.ejca.2019.07.004_bib18
  article-title: Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.15_suppl.9591
– volume: 377
  start-page: 1824
  issue: 19
  year: 2017
  ident: 10.1016/j.ejca.2019.07.004_bib1
  article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1709030
– volume: 91
  start-page: 168
  year: 2018
  ident: 10.1016/j.ejca.2019.07.004_bib6
  article-title: Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.11.023
– volume: 378
  start-page: 1789
  year: 2018
  ident: 10.1016/j.ejca.2019.07.004_bib3
  article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1802357
SSID ssj0007840
Score 2.397231
Snippet The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma...
1Background The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 83
SubjectTerms Benchmarks
Biopsy
Cancer
Continuity (mathematics)
Independent variables
Lymph nodes
Medical prognosis
Melanoma
Multivariate analysis
Parameters
Prognosis
Sentinel lymph node
Subgroups
Survival
Tumor burden
Tumors
Title Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0959804919304046
https://dx.doi.org/10.1016/j.ejca.2019.07.004
https://www.ncbi.nlm.nih.gov/pubmed/31677550
https://www.proquest.com/docview/2330968475
https://www.proquest.com/docview/2311658827
Volume 123
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED-VVkJ7QWPAKAPkSXtDoQ2JnWRvCIG6TeVhUIk3y3ZsqahNEG2ReOFv313iBCGxTtpjEl-U3J3vfrbvA-AbVyajDfwgzrMkiLWJAi0iFwwzzavWe6IqKTS-FqNJ_POO33XgosmFobBKb_trm15Za39n4Lk5eJhOBze0g5UiwEUIgpoYiw3onaG3T7vQO__xa3TdGuQkrfIi6x0vJPC5M3WYl703VH4ozKoanr5f2zv-6W_4s_JDVx9hywNIdl5_4zZ0bPEJNsf-iHwH5mM7U0U5VwElUVIgEFus0B6gRrFpwXwd1QWjDVhWh2w9WUYpSEg-Y7NnFC8rytwuvrPflHxOasFK9zpkuZqXj0xX-Q-7MLm6vL0YBb6nQmAQGC2D3OGKL0p0JtA1hVYPUTxK8NBYx3OVi9wabXSCMMAZND0udWFqOE9dpo1AMBjtQbcoC7sP7ExFCuUqlB3aOIuVQjTAE5Pj61XKnetD2HBSGl9wnPpezGQTWXYvifuSuC-HdA4e9-GkpXmoy22sHR01ApJNIimaPoneYC0Vb6neqNo_6Q4bHZB-oi8kcgQXgejieR--to9xitK5iypsuaIxVOMIlzJJHz7XutP-HBUiSHCVePCfH_UFPtBVHWBzCN3l48oeIUxa6mPYOH0Jj_1k-ANl0hE0
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED9BkQYviI2vDtg8aW9T1IbETsJbhUBl0D5sIPFm2Y4tFbUJ6sek_fe7S5wgpAESr7EvSs7nu5_P9wHwnSuTkQM_iPMsCWJtokCLyAX9TPOq9Z6oSgqNxmJ4F_-85_drcN7kwlBYpdf9tU6vtLV_0vPc7D1OJr3f5MFKEeAiBEFJjMU6bMTU1LoDG4Or6-G4VchJWuVF1h4vJPC5M3WYl30wVH4ozKoanr5f23_s00v4s7JDlzuw7QEkG9Tf-BHWbPEJPoz8FfkuzEZ2qopypgJKoqRAILZYoT5AiWKTgvk6qgtGDlhWh2z9sYxSkJB8yqZ_cXlZUeZ2ccZ-UfI5iQUr3dOU5WpWzpmu8h_24O7y4vZ8GPieCoFBYLQMcocnvijRmUDTFFrdx-VRgofGOp6rXOTWaKMThAHOoOpxqQtTw3nqMm0EgsFoHzpFWdhDYKcqUriuQtm-jbNYKUQDPDE5vl6l3LkuhA0npfEFx6nvxVQ2kWUPkrgvifuyT_fgcRd-tDSPdbmNV2dHzQLJJpEUVZ9Ea_AqFW-pnonam3THjQxIv9EXEjmCh0A08bwL39ph3KJ076IKW65oDtU4wqNM0oWDWnban6NCBAmeEj-_86O-wubwdnQjb67G10ewRSN1sM0xdJbzlT1ByLTUX_yW-AfTOBMa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Melanoma-specific+survival+in+patients+with+positive+sentinel+lymph+nodes%3A+Relevance+of+sentinel+tumor+burden&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Satzger%2C+Imke&rft.au=Leiter%2C+Ulrike&rft.au=Gr%C3%A4ger%2C+Nikolai&rft.au=Keim%2C+Ulrike&rft.date=2019-12-01&rft.pub=Elsevier+Science+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=123&rft.spage=83&rft_id=info:doi/10.1016%2Fj.ejca.2019.07.004&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon